Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRMA NASDAQ:GTBP NASDAQ:JAGX NASDAQ:ZVSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRMADermata Therapeutics$5.74+7.3%$6.38$5.09▼$24.90$3.65M0.5629,660 shs27,008 shsGTBPGT Biopharma$0.93-3.4%$2.05$0.91▼$4.10$3.44M1.33111,463 shs99,818 shsJAGXJaguar Animal Health$1.63+1.9%$2.28$1.57▼$35.25$3.48M0.43137,111 shs102,798 shsZVSAZyVersa Therapeutics$0.12-5.8%$0.34$0.11▼$3.37$913K0.753.25 million shs44,012 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRMADermata Therapeutics+7.59%+4.74%-6.27%-20.30%-67.57%GTBPGT Biopharma-3.40%-15.81%-53.28%-63.64%-57.33%JAGXJaguar Animal Health+1.87%-9.44%-23.83%-62.18%-94.23%ZVSAZyVersa Therapeutics-5.81%-17.03%-42.50%-82.25%-95.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRMADermata Therapeutics2.9958 of 5 stars3.55.00.00.02.50.80.6GTBPGT Biopharma2.3382 of 5 stars3.82.00.00.03.30.00.6JAGXJaguar Animal Health2.1105 of 5 stars3.53.00.00.02.20.00.6ZVSAZyVersa Therapeutics0.2909 of 5 stars0.04.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRMADermata Therapeutics 3.00Buy$10.0074.22% UpsideGTBPGT Biopharma 3.50Strong Buy$11.001,077.10% UpsideJAGXJaguar Animal Health 3.00Buy$60.003,580.98% UpsideZVSAZyVersa Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZVSA, GTBP, JAGX, and DRMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025DRMADermata TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $10.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRMADermata TherapeuticsN/AN/AN/AN/A$8.24 per shareN/AGTBPGT BiopharmaN/AN/AN/AN/A$0.80 per shareN/AJAGXJaguar Animal Health$11.69M0.30N/AN/A$2.02 per share0.81ZVSAZyVersa TherapeuticsN/AN/AN/AN/A$3.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRMADermata Therapeutics-$12.29M-$16.41N/A∞N/AN/A-214.98%-153.76%N/AGTBPGT Biopharma-$13.16M-$4.07N/AN/AN/AN/A-1,804.34%-200.12%11/13/2025 (Estimated)JAGXJaguar Animal Health-$38.49MN/A0.00N/AN/A-344.16%-660.18%-77.42%11/12/2025 (Estimated)ZVSAZyVersa Therapeutics-$9.41MN/A0.00N/AN/AN/A-109.54%-43.95%11/13/2025 (Estimated)Latest ZVSA, GTBP, JAGX, and DRMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025GTBPGT Biopharma-$0.68-$0.55+$0.13-$0.55N/AN/A8/14/2025Q2 2025JAGXJaguar Animal Health-$7.13-$10.26-$3.13-$10.26$3.27 million$2.98 million8/13/2025Q2 2025DRMADermata Therapeutics-$2.90-$1.66+$1.24-$1.66N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRMADermata TherapeuticsN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/AJAGXJaguar Animal HealthN/AN/AN/AN/AN/AZVSAZyVersa TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRMADermata TherapeuticsN/A6.476.47GTBPGT BiopharmaN/A2.762.76JAGXJaguar Animal Health2.440.950.59ZVSAZyVersa TherapeuticsN/A0.180.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRMADermata Therapeutics8.67%GTBPGT Biopharma8.15%JAGXJaguar Animal Health12.04%ZVSAZyVersa Therapeutics3.91%Insider OwnershipCompanyInsider OwnershipDRMADermata Therapeutics18.50%GTBPGT Biopharma3.40%JAGXJaguar Animal Health4.55%ZVSAZyVersa Therapeutics0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRMADermata Therapeutics8682,000556,000Not OptionableGTBPGT Biopharma83.56 million3.44 millionNo DataJAGXJaguar Animal Health502.17 million2.08 millionNo DataZVSAZyVersa Therapeutics27.94 million4.86 millionNot OptionableZVSA, GTBP, JAGX, and DRMA HeadlinesRecent News About These CompaniesZyVersa Therapeutics (NASDAQ:ZVSA) Trading Down 6.1% - Should You Sell?August 29 at 3:41 AM | americanbankingnews.comZyVersa Therapeutics Reports Financial Challenges Amid Nasdaq DelistingAugust 20, 2025 | msn.comZyVersa Therapeutics reports Q2 EPS (46c) vs. ($3.31) last yearAugust 14, 2025 | msn.comZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address ...August 14, 2025 | bakersfield.comBZyVersa Therapeutics highlights data on role of lipotoxicity in DKDAugust 14, 2025 | msn.comZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its ProgressionAugust 14, 2025 | globenewswire.comZyVersa Therapeutics Activates First Clinical Site for Phase 2a Trial of VAR 200 in Diabetic Kidney Disease and Reports Progress in Product DevelopmentAugust 13, 2025 | quiverquant.comQZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building MilestonesAugust 13, 2025 | globenewswire.comZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D ProgressJuly 21, 2025 | globenewswire.comZyVersa Touches 52-Week Low; Nasdaq to Suspend Trading ThursdayJuly 16, 2025 | marketwatch.comZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds | MorningstarJuly 9, 2025 | morningstar.comMZyVersa’s VAR 200 approved for emergency use in rare kidney diseaseJuly 9, 2025 | uk.investing.comZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis - NasdaqJuly 9, 2025 | nasdaq.comWhy Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?July 8, 2025 | benzinga.comZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross ProceedsJuly 8, 2025 | globenewswire.comZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a Patient with ApoCII AmyloidosisJuly 8, 2025 | finanznachrichten.deZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII AmyloidosisJuly 8, 2025 | quiverquant.comQZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII AmyloidosisJuly 8, 2025 | globenewswire.comZyVersa Therapeutics Enters Share Purchase Agreement with Williamsburg Venture Holdings to Advance Clinical Development of VAR 200 - NasdaqJune 27, 2025 | nasdaq.comZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol ...June 26, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZVSA, GTBP, JAGX, and DRMA Company DescriptionsDermata Therapeutics NASDAQ:DRMA$5.74 +0.39 (+7.29%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$5.63 -0.11 (-1.92%) As of 08/29/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.GT Biopharma NASDAQ:GTBP$0.93 -0.03 (-3.40%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.94 +0.00 (+0.48%) As of 08/29/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Jaguar Animal Health NASDAQ:JAGX$1.63 +0.03 (+1.88%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.64 +0.01 (+0.86%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.ZyVersa Therapeutics NASDAQ:ZVSA$0.12 -0.01 (-5.81%) As of 08/29/2025 03:54 PM EasternZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
